Recombinant CTLA-4 Fc Fusion Protein (Belatacept Biosimilar)
Catalog #500008
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500008 | 1 mg | $400.00 | ||
| 500008 | 5 mg | $800.00 | ||
| 500008 | 20 mg | $1,600.00 |
Product Details
Belatacept biosimilar is a recombinant fusion protein designed as an alternative to the reference biologic Belatacept (Nulojix®). It consists of the extracellular domain of human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) fused to the Fc domain of human IgG1. This biosimilar selectively inhibits CD28-mediated T-cell activation by blocking the interaction between CD80/CD86 and CD28, making it a potent immunosuppressive agent for research applications.
Specifications
| Clone | Belatacept |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.4 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |